Optimisation of the Factor VIII yield in mammalian cell cultures by reducing the membrane bound fraction

Journal of Biotechnology

Volumn 151, Issue 4, 2011, Pages 357-362

  Kolind, Mille Petersen ^a,b   Nørby, Peder Lisby ^a   Berchtold, Martin Werner ^b   Johnsen, Laust Bruun ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Annexin V; Factor VIII; OPLS; Protein expression; Serum free medium; Von Willebrand factor

Indexed keywords

ANNEXINS; FACTOR VIII; OPLS; PROTEIN EXPRESSION; SERUM FREE MEDIUM; VON WILLEBRAND FACTOR;

AMINO ACIDS; ANIMAL CELL CULTURE; ANTIBIOTICS; BODY FLUIDS; CELL MEMBRANES; MAMMALS; MEMBRANES; PROTEINS;

CELL CULTURE;

2 PHOSPHOSERINE; LIPOCORTIN 5; PHOSPHATIDYLSERINE; RECOMBINANT BLOOD CLOTTING FACTOR 8; SERINE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL MEMBRANE; CELL SECRETION; CELL STRAIN HEK293; CHO CELL; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; MAMMAL CELL; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SERUM;

ANIMALS; ANNEXIN A5; CELL CULTURE TECHNIQUES; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; CULTURE MEDIA, SERUM-FREE; FACTOR VIII; GENETIC VECTORS; HEK293 CELLS; HUMANS; PROTEIN BINDING; SERINE; THROMBIN; TRANSFECTION; VON WILLEBRAND FACTOR;

MAMMALIA;

EID: 79951551843     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2010.12.019     Document Type: Article

References (25)

1. Adamson R. Design and operation of a recombinant mammalian cell manufacturing process for rFVIII. Ann. Hematol. 1994, 68(Suppl. 3):S9-14.
2. Andree H.A., Stuart M.C., Hermens W.T., Reutelingsperger C.P., Hemker H.C., Frederik P.M., Willems G.M. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J. Biol. Chem. 1992, 267:17907-17912.
3. Church W.R., Jernigan R.L., Toole J., Hewick R.M., Knopf J., Knutson G.J., Nesheim M.E., Mann K.G., Fass D.N. Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:6934-6937.
4. Fay P.J. Reconstitution of human factor VIII from isolated subunits. Arch. Biochem. Biophys. 1988, 262:525-531.
5. Fay P.J. Factor VIII structure and function. Thromb. Haemost. 1993, 70:63-67.
6. Foster P.A., Zimmerman T.S. Factor VIII structure and function. Blood Rev. 1989, 3:180-191.
7. Gilbert G.E., Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-l-serine, a moiety of phosphatidylserine. Biochemistry 1993, 32:9577-9585.
8. Hamer R.J., Koedam J.A., Beeser-Visser N.H., Bertina R.M., Van Mourik J.A., Sixma J.J. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur. J. Biochem. 1987, 166:37-43.
9. Hill-Eubanks D.C., Parker C.G., Lollar P. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:6508-6512.
10. Hvarregaard J., Andersen M.H., Berglund L., Rasmussen J.T., Petersen T.E. Characterization of glycoprotein PAS-6/7 from membranes of bovine milk fat globules. Eur. J. Biochem. 1996, 240:628-636.
11. Ishaque A., Thrift J., Murphy J.E., Konstantinov K. Cell surface staining of recombinant factor VIII is reduced in apoptosis resistant BHK-21 cells. J. Biotechnol. 2008, 137:20-27.
12. Kane W.H., Davie E.W. Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:6800-6804.
13. Kaufman R.J., Wasley L.C., Davies M.V., Wise R.J., Israel D.I., Dorner A.J. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol. Cell. Biol. 1989, 9:1233-1242.
14. Kaufman R.J., Wasley L.C., Dorner A.J. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J. Biol. Chem. 1988, 263:6352-6362.
15. Kolind M.P., Noerby P.L., Lundgaard T.V., Berchtold M.W., Johnsen L.B. The B-domain of Factor VIII reduces cell membrane attachment to host cells under serum free conditions. J. Biotechnol. 2010, 147:198-204.
16. Larner A.J. The molecular pathology of haemophilia. Q. J. Med. 1987, 63:473-491.
17. Lollar P., Hill-Eubanks D.C., Parker C.G. Association of the factor VIII light chain with von Willebrand factor. J. Biol. Chem. 1988, 263:10451-10455.
18. Miao H.Z., Sirachainan N., Palmer L., Kucab P., Cunningham M.A., Kaufman R.J., Pipe S.W. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004, 103:3412-3419.
19. Miclea R.D., Purohit V.S., Balu-Iyer S.V. O-phospho-l-serine, multi-functional excipient for B domain deleted recombinant factor VIII. AAPS J. 2007, 9:E251-E259.
20. Reutelingsperger C.P., Hornstra G., Hemker H.C. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur. J. Biochem. 1985, 151:625-629.
21. Stubbs J.D., Lekutis C., Singer K.L., Bui A., Yuzuki D., Srinivasan U., Parry G. cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:8417-8421.
22. Swaroop M., Moussalli M., Pipe S.W., Kaufman R.J. Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J. Biol. Chem. 1997, 272:24121-24124.
23. Toole J.J., Pittman D.D., Orr E.C., Murtha P., Wasley L.C., Kaufman R.J. A large region (approximately equal to 95kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:5939-5942.
24. Tuddenham E.G., Lane R.S., Rotblat F., Johnson A.J., Snape T.J., Middleton S., Kernoff P.B. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br. J. Haematol. 1982, 52:259-267.
25. Winge, S., 2006. Method for Isolation of Recombinantly Produced Proteins. Octapharma AG. 05102475.0 [EP 1 707 634 A1]. 29-3-2006. 29-3-2005.